ES2360291T3 - TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1. - Google Patents

TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1. Download PDF

Info

Publication number
ES2360291T3
ES2360291T3 ES04749338T ES04749338T ES2360291T3 ES 2360291 T3 ES2360291 T3 ES 2360291T3 ES 04749338 T ES04749338 T ES 04749338T ES 04749338 T ES04749338 T ES 04749338T ES 2360291 T3 ES2360291 T3 ES 2360291T3
Authority
ES
Spain
Prior art keywords
iga1
iga1 protease
protease
marker
deposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04749338T
Other languages
English (en)
Spanish (es)
Inventor
Andrew G. Plaut
Jiazhou Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Application granted granted Critical
Publication of ES2360291T3 publication Critical patent/ES2360291T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
ES04749338T 2003-03-07 2004-03-05 TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1. Expired - Lifetime ES2360291T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45305503P 2003-03-07 2003-03-07
US453055P 2003-03-07

Publications (1)

Publication Number Publication Date
ES2360291T3 true ES2360291T3 (es) 2011-06-02

Family

ID=33418058

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04749338T Expired - Lifetime ES2360291T3 (es) 2003-03-07 2004-03-05 TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1.

Country Status (10)

Country Link
US (3) US7407653B2 (enExample)
EP (1) EP1603511B1 (enExample)
JP (4) JP5438886B2 (enExample)
KR (2) KR20130026513A (enExample)
CN (1) CN1777673B (enExample)
AT (1) ATE496992T1 (enExample)
CA (1) CA2558873C (enExample)
DE (1) DE602004031199D1 (enExample)
ES (1) ES2360291T3 (enExample)
WO (1) WO2004096157A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130026513A (ko) 2003-03-07 2013-03-13 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 ＩｇＡ1 침착 질환 치료
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
US20100261252A1 (en) * 2009-04-10 2010-10-14 Biomarin Pharmaceutical Inc. Methods of enhancing yield of active iga protease
WO2010123885A2 (en) * 2009-04-20 2010-10-28 Tufts Medical Center, Inc. Iga1 protease polypeptide agents and uses thereof
CN104073474A (zh) * 2014-06-27 2014-10-01 樊均明 一种IgA1酶及其制备方法和应用
US20170369551A1 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. METHODS OF TREATING IgA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA NEPHRITIS USING A B-CELL ACTIVATING FACTOR (BAFF) INHIBITOR
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
US20250242002A1 (en) * 2022-01-29 2025-07-31 Peking University First Hospital Truncated forms of iga protease, fusion proteins comprising a truncated form of iga protease and uses thereof
KR20250114034A (ko) 2022-11-11 2025-07-28 아이간 바이오사이언스 Iga 프로테아제 폴리펩타이드 제제
WO2025183146A1 (ja) * 2024-02-29 2025-09-04 積水メディカル株式会社 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DK130889A (da) * 1989-03-17 1990-09-18 Mogens Kilian Immunoglobulin a1-proteaser (iga1-proteaser), fremgangsmaade til genteknologisk fremstilling af saadanne enzymer samt vaccine indeholdende enzymerne og fragmenter deraf til immunisering mod bakteriel meningitis og andre sygdomme fremkaldt af iga1-protease-producerende bakterier
ATE396399T1 (de) * 1998-03-31 2008-06-15 Asahi Kasei Pharma Corp Verfahren zur untersuchung der iga-nephropathie
DK2067788T3 (da) 1999-05-18 2015-10-19 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
KR20130026513A (ko) * 2003-03-07 2013-03-13 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 ＩｇＡ1 침착 질환 치료

Also Published As

Publication number Publication date
US20090041746A1 (en) 2009-02-12
JP2015096079A (ja) 2015-05-21
US20090130084A1 (en) 2009-05-21
WO2004096157A3 (en) 2005-10-20
EP1603511A4 (en) 2007-06-06
US8216568B2 (en) 2012-07-10
US7407653B2 (en) 2008-08-05
EP1603511A2 (en) 2005-12-14
CN1777673A (zh) 2006-05-24
HK1090950A1 (zh) 2007-01-05
JP2013230157A (ja) 2013-11-14
EP1603511B1 (en) 2011-01-26
ATE496992T1 (de) 2011-02-15
CA2558873C (en) 2015-10-20
CN1777673B (zh) 2010-04-28
KR20060015468A (ko) 2006-02-17
WO2004096157A2 (en) 2004-11-11
DE602004031199D1 (de) 2011-03-10
KR20130026513A (ko) 2013-03-13
CA2558873A1 (en) 2004-11-11
US20050136062A1 (en) 2005-06-23
JP5438886B2 (ja) 2014-03-12
JP2011101645A (ja) 2011-05-26
JP2006519619A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
US8216568B2 (en) Combination therapy with IgA1 proteases
JP5739854B2 (ja) 融合タンパク質
CN116355966A (zh) 一种融合蛋白在遗传编辑的用途
JPH04500157A (ja) チモーゲン的またはフィブリン特異的特性を有する組織プラスミノーゲン活性化因子
JP2008535475A (ja) Ｑ３ｓｐａｒｃ欠失変異体及びその使用
US6884619B2 (en) Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
Jeltsch et al. Mutational analysis of the function of Gln115 in the EcoRI restriction endonuclease, a critical amino acid for recognition of the inner thymidine residue in the sequence-GAATTC-and for coupling specific DNA binding to catalysis
AU2002364727A1 (en) Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JPH10505752A (ja) システイン・プロテアーゼあるいはその断片を含む連鎖球菌を識別するための方法および組成物
WO2023077413A1 (zh) 可与底物结合的蛋白序列在制备抑制纤维蛋白组装的产品中的应用
JP2002516076A (ja) 緑膿菌のＭｕｒＤタンパク質及び遺伝子
CN119053700A (zh) 大肠杆菌表达的重组人体微纤溶酶、其生产方法、包含其的药物组合物及试剂盒、利用其治疗血栓栓塞相关疾病的方法及应用
HK1090950B (en) Treatment of iga1 deposition diseases
WO2006090282A2 (en) Recombinant inhibitor proteins of an hk14 protease and use thereof
Coppolino PbsP, a major virulence factor of Streptococcus agalactiae, is regulated by the SaeRS two-component system
AU2013305744A1 (en) Engineered anthrax lethal toxin for targeted delivery
KR20250114034A (ko) Iga 프로테아제 폴리펩타이드 제제
AU2002318241B2 (en) Inhibition of behab cleavage and primary central nervous system (CNS) tumors
AU2002318241A1 (en) Inhibition of behab cleavage and primary central nervous system (CNS) tumors